The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1236
June 5, 2006
View Complete Issue         Table of Contents 2019 
Lubiprostone (Amitiza) for Chronic Constipation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lubiprostone (Amitiza) for Chronic Constipation
June 5, 2006 (Issue: 1236)
The FDA has approved lubiprostone (Amitiza - Sucampo/Takeda), a chloride channel activator, for treatment of chronic idiopathic constipation in adults. The only other prescription drug approved by the FDA for this indication (in 2004 for adults...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lubiprostone (Amitiza) for Chronic Constipation
Article code: 1236c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.